1r3c: Difference between revisions
New page: left|200px<br /> <applet load="1r3c" size="450" color="white" frame="true" align="right" spinBox="true" caption="1r3c, resolution 2.00Å" /> '''THE STRUCTURE OF P3... |
No edit summary |
||
| Line 1: | Line 1: | ||
[[Image:1r3c.gif|left|200px]]<br /> | [[Image:1r3c.gif|left|200px]]<br /><applet load="1r3c" size="350" color="white" frame="true" align="right" spinBox="true" | ||
<applet load="1r3c" size=" | |||
caption="1r3c, resolution 2.00Å" /> | caption="1r3c, resolution 2.00Å" /> | ||
'''THE STRUCTURE OF P38ALPHA C162S MUTANT'''<br /> | '''THE STRUCTURE OF P38ALPHA C162S MUTANT'''<br /> | ||
==Overview== | ==Overview== | ||
Mitogen-activated protein (MAP) kinase p38 alpha is activated in response | Mitogen-activated protein (MAP) kinase p38 alpha is activated in response to environmental stress and cytokines, and plays a significant role in inflammatory responses. For these reasons, it is an important target for the treatment of a wide range of inflammatory and autoimmune diseases. The crystals of p38 alpha that we obtained by published procedures were usually small, quite mosaic, and difficult to reproduce and thus posed a difficulty for the intensive high-resolution studies required for a structure-guided drug discovery approach. Based on crystallographic and biochemical evidences, we prepared a single point mutation of a surface cysteine (C162S) and found that it prevents aggregation and improves the homogeneity and stability of the enzyme. This mutation also facilitates the crystallization process and increases the diffracting power of p38 alpha crystals. Surprisingly, we found that the mutation induces a change in the conformation of a nearby surface loop resulting in stronger lattice interactions, consistent with the improved crystal quality. The mutant protein, because of its improved stability and strengthened lattice interactions, thus provides a significantly improved reagent for use in structure-based drug design for this important disease target. | ||
==About this Structure== | ==About this Structure== | ||
1R3C is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] with MG as [http://en.wikipedia.org/wiki/ligand ligand]. Active as [http://en.wikipedia.org/wiki/Non-specific_serine/threonine_protein_kinase Non-specific serine/threonine protein kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.11.1 2.7.11.1] Full crystallographic information is available from [http:// | 1R3C is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] with <scene name='pdbligand=MG:'>MG</scene> as [http://en.wikipedia.org/wiki/ligand ligand]. Active as [http://en.wikipedia.org/wiki/Non-specific_serine/threonine_protein_kinase Non-specific serine/threonine protein kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.11.1 2.7.11.1] Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1R3C OCA]. | ||
==Reference== | ==Reference== | ||
| Line 15: | Line 14: | ||
[[Category: Non-specific serine/threonine protein kinase]] | [[Category: Non-specific serine/threonine protein kinase]] | ||
[[Category: Single protein]] | [[Category: Single protein]] | ||
[[Category: Becker, J | [[Category: Becker, J W.]] | ||
[[Category: Cameron, P | [[Category: Cameron, P M.]] | ||
[[Category: Frantz-Wattley, B.]] | [[Category: Frantz-Wattley, B.]] | ||
[[Category: Neill, E | [[Category: Neill, E O.]] | ||
[[Category: Patel, S | [[Category: Patel, S B.]] | ||
[[Category: Scapin, G.]] | [[Category: Scapin, G.]] | ||
[[Category: MG]] | [[Category: MG]] | ||
| Line 26: | Line 25: | ||
[[Category: stabilization]] | [[Category: stabilization]] | ||
''Page seeded by [http:// | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 14:46:33 2008'' | ||
Revision as of 15:46, 21 February 2008
|
THE STRUCTURE OF P38ALPHA C162S MUTANT
OverviewOverview
Mitogen-activated protein (MAP) kinase p38 alpha is activated in response to environmental stress and cytokines, and plays a significant role in inflammatory responses. For these reasons, it is an important target for the treatment of a wide range of inflammatory and autoimmune diseases. The crystals of p38 alpha that we obtained by published procedures were usually small, quite mosaic, and difficult to reproduce and thus posed a difficulty for the intensive high-resolution studies required for a structure-guided drug discovery approach. Based on crystallographic and biochemical evidences, we prepared a single point mutation of a surface cysteine (C162S) and found that it prevents aggregation and improves the homogeneity and stability of the enzyme. This mutation also facilitates the crystallization process and increases the diffracting power of p38 alpha crystals. Surprisingly, we found that the mutation induces a change in the conformation of a nearby surface loop resulting in stronger lattice interactions, consistent with the improved crystal quality. The mutant protein, because of its improved stability and strengthened lattice interactions, thus provides a significantly improved reagent for use in structure-based drug design for this important disease target.
About this StructureAbout this Structure
1R3C is a Single protein structure of sequence from Homo sapiens with as ligand. Active as Non-specific serine/threonine protein kinase, with EC number 2.7.11.1 Full crystallographic information is available from OCA.
ReferenceReference
Lattice stabilization and enhanced diffraction in human p38 alpha crystals by protein engineering., Patel SB, Cameron PM, Frantz-Wattley B, O'Neill E, Becker JW, Scapin G, Biochim Biophys Acta. 2004 Jan 14;1696(1):67-73. PMID:14726206
Page seeded by OCA on Thu Feb 21 14:46:33 2008